Literature DB >> 25399071

Genetic association between cyclin D1 polymorphism and breast cancer susceptibility.

XiaoRui Li1, XiaoQing Huo, WeiWei Li, QingHui Yang, Ying Wang, XiaoChun Kang.   

Abstract

Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. This study was undertaken to derive a precise risk estimate for the cyclin D1 polymorphism associated with breast cancer risk. We performed a search of EMBASE, PubMed, and Web of Science. In total, data from 18 publications were pooled and the association was assessed by odds ratios (ORs) with 95 % confidence intervals (CIs). This analysis showed that there was no obvious association between the cyclin D1 polymorphism and breast cancer risk in any of the analyzed genetic model. We found the same negative association in stratified analyses by ethnicity, source of controls, and sample size. Our meta-analysis provides an estimate that the presence of cyclin D1 polymorphism may not confer susceptibility to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25399071     DOI: 10.1007/s13277-014-2489-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  49 in total

Review 1.  The role of p34 kinases in the G1 to S-phase transition.

Authors:  S I Reed
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

4.  Association of cyclin D1 genotype with breast cancer risk and survival.

Authors:  Xiao Ou Shu; Derek B Moore; Qiuyin Cai; Jiarong Cheng; Wanqing Wen; Larry Pierce; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-01       Impact factor: 4.254

Review 5.  Cycling to cancer with cyclin D1.

Authors:  J Alan Diehl
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

6.  Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.

Authors:  Alan G Casson; Zuoyu Zheng; Susan C Evans; Laurette Geldenhuys; Sander Veldhuyzen van Zanten; Paul J Veugelers; Geoffrey A Porter; Duane L Guernsey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

Review 7.  Cyclin D1 and breast cancer.

Authors:  Pankaj G Roy; Alastair M Thompson
Journal:  Breast       Date:  2006-05-03       Impact factor: 4.380

8.  Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls.

Authors:  Jing Cui; Liang Shen; Yu Wang
Journal:  Asian Pac J Cancer Prev       Date:  2012

9.  Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.

Authors:  A M L Bedewy; M H Mostafa; A A Saad; S M El-Maghraby; M M L Bedewy; A M Hilal; L S Kandil
Journal:  J BUON       Date:  2013 Jan-Mar       Impact factor: 2.533

Review 10.  Cyclin D1, EMS1 and 11q13 amplification in breast cancer.

Authors:  Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland
Journal:  Breast Cancer Res Treat       Date:  2003-04       Impact factor: 4.872

View more
  6 in total

1.  Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.

Authors:  Gang Cheng; Leiming Zhang; Wenying Lv; Chao Dong; Yaming Wang; Jianning Zhang
Journal:  Med Oncol       Date:  2014-12-13       Impact factor: 3.064

2.  Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer.

Authors:  Liying Guo; Sha Liu; Adina Jakulin; Dilimina Yilamu; Bowei Wang; Jinghong Yan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Downregulation of miR-503 Promotes ESCC Cell Proliferation, Migration, and Invasion by Targeting Cyclin D1.

Authors:  Lanfang Jiang; Zitong Zhao; Leilei Zheng; Liyan Xue; Qimin Zhan; Yongmei Song
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-06-09       Impact factor: 7.691

4.  MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer.

Authors:  Lihua Jiang; Wenchuan Yang; Weishi Bian; Hailin Yang; Xia Wu; Yuhua Li; Wen Feng; Xuejian Liu
Journal:  Oncol Res       Date:  2018-03-01       Impact factor: 5.574

5.  microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway.

Authors:  Yiyu Chen; Jingwen Jiang; Mengyang Zhao; Xiaojun Luo; Zixi Liang; Yan Zhen; Qiaofen Fu; Xiaojie Deng; Xian Lin; Libo Li; Rongcheng Luo; Zhen Liu; Weiyi Fang
Journal:  Oncotarget       Date:  2016-07-05

6.  Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR‑302‑3p on cyclin D1.

Authors:  Wenjing Chen; Lili Zhai; Huiming Liu; Yuting Li; Qi Zhang; Dandan Xu; Weiye Fan
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.